| P50 | author | Franz J St John | Q47503015 |
| | Alex MacKerell | Q57907659 |
| P2093 | author name string | Jun Zhang | |
| | Steven Fletcher | |
| | Edwin Pozharski | |
| | Paul Shapiro | |
| | U Deva Priyakumar | |
| | Amanda Brophy | |
| | E Prabhu Raman | |
| | Kwan-Young Jung | |
| | Ramin Samadani | |
| | Taiji Oashi | |
| P2860 | cites work | Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm | Q22010423 |
| | Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions | Q24536356 |
| | CHARMM: the biomolecular simulation program | Q24658108 |
| | Comparison of simple potential functions for simulating liquid water | Q26778447 |
| | Docking interactions induce exposure of activation loop in the MAP kinase ERK2 | Q83964224 |
| | Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2 | Q27630416 |
| | Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors | Q27643818 |
| | Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases | Q27665974 |
| | X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor | Q27678046 |
| | Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers | Q27685364 |
| | Atomic structure of the MAP kinase ERK2 at 2.3 A resolution | Q27730946 |
| | Activation mechanism of the MAP kinase ERK2 by dual phosphorylation | Q27743261 |
| | All-atom empirical potential for molecular modeling and dynamics studies of proteins | Q27860468 |
| | Scalable molecular dynamics with NAMD | Q27860718 |
| | Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 |
| | ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation | Q28140491 |
| | Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1 | Q28217158 |
| | The Fos family of transcription factors and their role in tumourigenesis | Q28275076 |
| | Differential regulation and properties of MAPKs | Q28301932 |
| | Computational fragment-based binding site identification by ligand competitive saturation | Q28475699 |
| | ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation | Q28578241 |
| | Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 |
| | Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions | Q29547189 |
| | Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations | Q29547631 |
| | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 |
| | Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 |
| | Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. | Q33339438 |
| | Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro | Q33540867 |
| | Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics | Q33756524 |
| | Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. | Q33789572 |
| | Docking domains and substrate-specificity determination for MAP kinases | Q34023280 |
| | Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity | Q34509259 |
| | Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role | Q34571223 |
| | Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. | Q34600125 |
| | Cell fate decisions are specified by the dynamic ERK interactome | Q35014377 |
| | Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase | Q35186927 |
| | Ets proteins in biological control and cancer | Q35701558 |
| | Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure | Q35762145 |
| | Examining Docking Interactions on ERK2 with Modular Peptide Substrates | Q36174472 |
| | Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | Q36236645 |
| | Targeting the ERK signaling pathway in cancer therapy | Q36486780 |
| | Unique MAP Kinase binding sites | Q36494279 |
| | Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling | Q36872318 |
| | Identification of a new JNK inhibitor targeting the JNK-JIP interaction site | Q36938538 |
| | Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters | Q36980280 |
| | Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay | Q37104928 |
| | Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. | Q37250634 |
| | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors | Q37629722 |
| | Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors | Q37665845 |
| | Targeting BRAF for patients with melanoma. | Q37817713 |
| | Mutant BRAF Melanomas—Dependence and Resistance | Q37830845 |
| | Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Q37866945 |
| | "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway | Q38220879 |
| | Discovery and characterization of a substrate selective p38alpha inhibitor | Q39128960 |
| | Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors | Q39161270 |
| | Manipulating JNK signaling with (--)-zuonin A. | Q39292273 |
| | ERK inhibition overcomes acquired resistance to MEK inhibitors. | Q39383179 |
| | ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos | Q39878927 |
| | Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex | Q40378580 |
| | Identification of novel extracellular signal-regulated kinase docking domain inhibitors. | Q40401482 |
| | Regulation of Raf-1 by direct feedback phosphorylation. | Q40467820 |
| | Ternary complex factors: growth factor regulated transcriptional activators | Q40757584 |
| | Signal Transduction through MAP Kinase Cascades | Q41750250 |
| | DEF pocket in p38α facilitates substrate selectivity and mediates autophosphorylation. | Q41831642 |
| | Reproducing Crystal Binding Modes of Ligand Functional Groups Using Site-Identification by Ligand Competitive Saturation (SILCS) Simulations | Q42130025 |
| | Feedback Regulation of Raf-1 and Mitogen-activated Protein Kinase (MAP) Kinase Kinases 1 and 2 by MAP Kinase Phosphatase-1 (MKP-1) | Q42449463 |
| | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 |
| | A Bipartite Mechanism for ERK2 Recognition by Its Cognate Regulators and Substrates | Q42599495 |
| | The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs | Q42799852 |
| | Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo | Q42811832 |
| | Molecular interpretation of ERK signal duration by immediate early gene products | Q42812329 |
| | Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues | Q43616462 |
| | Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. | Q44950105 |
| | Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. | Q45013677 |
| | The docking interaction of caspase-9 with ERK2 provides a mechanism for the selective inhibitory phosphorylation of caspase-9 at threonine 125. | Q46847481 |
| | Consideration of molecular weight during compound selection in virtual target-based database screening | Q47173464 |
| | Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry | Q47805536 |
| | Inhibition of the bacterial heme oxygenases from Pseudomonas aeruginosa and Neisseria meningitidis: novel antimicrobial targets. | Q53540925 |
| | Binding Response: A Descriptor for Selecting Ligand Binding Site on Protein Surfaces | Q58846313 |
| | Selective targeting of MAPKs to the ETS domain transcription factor SAP-1 | Q73072017 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immediate early gene | Q409638 |
| P304 | page(s) | 425-438 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf | |
| P478 | volume | 467 | |